Abstract:Objective To investigating the prognostic value of the CellSearch CTC enumeration system for the castration resistant prostate cancer (CRPC) patients.Methods From January 2013 to June 2014,92 CRPC patients'peripheral blood were collected and tested by CellSearch CTC detection system.The median age was 69 (range 53-85) years old and the median PSA was 19.1 (range 2.6-273.0) ng/ml.The median serum hemoglobin was 124(69-156)g/L,the serum alkaline phosphatase was 87.0 (29.0-2778.5) U/L,the serum lactate dehydrogenase was 207 (114-2467) U/ L and the serum albumin was 44.0 (32.3-52.2)g/L respectively.Among all the patients,39.1％ (36/92) was Gleason score below 8,32.6％ (30/ 92)was 8 and 28.3％ (26/92) was over 8.93.5％ (86/92) of the patients were diagnosed as bone metastasis and 31.5％ (29/92)as lymph node metastasis.Another 5 healthy volunteers with no evidence of tumor history were also tested as the control group.During the follow up,42 patients were treated with docetaxel plus prednisone as their first-line therapeutic regimen,and the remaining 50 patients who were intolerant to or refused chemotherapy were treated with ketoconazole,estrogen or traditional Chinese medicine.For the survival analysis,Kaplan-Meier plots were generated based on CTC enumeration at baseline and Log-rank test was conducted for calculating the survival difference between the groups.The independent prognostic factors were analyzed by the univariate and multivariate Cox analysis.Results At the time of follow-up,41 patients had died of prostate cancer with the median follow up of 16.2 mouths (range:7.0-26.0 months).All the five patients were detected with no CTC.Ninety-two patients were divided into two groups based on CTC enumeration.Fifty-six patients were defined as favorable CTC counts group (CTC ＜ 5) with median follow up of 25 months and 36 as unfavorable CTC counts group (CTC ≥ 5) with median follow up of 18 months.Unfavorable CTC enumerations were predictive of shorter overall survival (Log-rank P =0.00).In the univariate analysis,lactate dehydrogenase (P =0.02),hemoglobin (P =0.00),alkaline phosphatase(P =0.00),serum albumin(P =0.01),ECOG performance status(P =0.00) and CTC enumeration(P =0.00) were associated with prognosis of CRPC patients.A multivariate analysis indicated that only baseline serum alumin (P =0.01),ECOG performance status(P =0.01) and CTC enumeration (P =0.00) were independent prognostic factors for overall survival.Subgroup analysis still support the notion that CTC ≥ 5 are indicative of poor prognosis regardless of receiving docetaxel plus prednisone as their first-line therapeutic regimen or not(P ＜ 0.05).Conclusions In the current study,we validated that CTC enumeration could provide a useful prognostic determinant for CRPC patients.

Monitoring Circulating Prostate Cancer Cells by in Vivo Flow Cytometry Assesses Androgen Deprivation Therapy on Metastasis

Monitoring circulating prostate tumor cells after tumor resection by in vivo flow cytometry

Real-time Monitoring of Circulation Tumor Cells in a Surgical Orthotopic Implantation Model of Human Metastatic Prostate Cancer

Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential

Studying Depletion Kinetics Of Circulating Prostate Cancer Cells By In Vivo Flow Cytometer

Monitoring Tumor Metastasis by in Vivo Imaging and Flow Cytometer

Real-Time Monitoring Of Rare Circulating Hepatocellular Carcinoma Cells In An Orthotopic Model By In Vivo Flow Cytometry Assesses Resection On Metastasis

Studying the Role of Macrophages in Circulating Prostate Cancer Cells by in Vivo Flow Cytometry

Monitoring radiofrequency therapy‐induced tumor cell dissemination by in vivo flow cytometry

Phenotypes of Circulating Tumour Cells Predict Time to Castration Resistance in Metastatic Castration-Sensitive Prostate Cancer.

Data from Real-Time Monitoring of Rare Circulating Hepatocellular Carcinoma Cells in an Orthotopic Model by <i>in Vivo</i> Flow Cytometry Assesses Resection on Metastasis

Circulating Tumor Cells in Prostate Cancer: Precision Diagnosis and Therapy.

Data from Real-Time Monitoring of Rare Circulating Hepatocellular Carcinoma Cells in an Orthotopic Model by <i>In Vivo</i> Flow Cytometry Assesses Resection on Metastasis

Combination of Circulating Tumor Cell Enumeration and Tumor Marker Detection in Predicting Prognosis and Treatment Effect in Metastatic Castration-Resistant Prostate Cancer

Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

Real Time Monitoring of Daily Variation of Circulating Tumor Cells by in Vivo Flow Cytometry (conference Presentation)

Prognostic Value of Circulating Tumor Cell Enumeration for Castration Refractory Prostate Cancer

Circulation Times of Prostate Cancer and Hepatocellular Carcinoma Cells by in Vivo Flow Cytometry

Prognostic Role of Circulating Tumor Cells and Disseminated Tumor Cells in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis

Expression of stem cell markers as predictors of therapeutic response in metastatic prostate cancer patients

A Higher Number of Circulating Tumor Cells (CTC) in Peripheral Blood Indicates Poor Prognosis in Prostate Cancer Patients--a Meta-Analysis.